Your browser doesn't support javascript.
loading
Protecting children and adults with primary antibody deficiencies against common and emergent pathogens and non-infectious complications.
Neth, Olaf; Mahlaoui, Nizar; Cunningham-Rundles, Charlotte.
Afiliação
  • Neth O; Pediatric Infectious Diseases, Rheumatology and Immunology, University Hospital Virgen del Rocío, Institute of Biomedicine of Seville (IBiS), Sevilla, Spain.
  • Mahlaoui N; French National Reference Center for Primary Immunodeficiencies (CEREDIH), Necker-Enfants Malades University Hospital, Assistance Publique-Hôpitaux de Paris (APHP), Paris, France; Pediatric Immuno-Hematology and Rheumatology Unit, Necker-Enfants Malades University Hospital, Assistance Publique-Hôpitaux de Paris (APHP), Paris, France.
  • Cunningham-Rundles C; Department of Medicine and Pediatrics, Icahn School of Medicine at Mount-Sinai, New York, NY, USA.
Clin Exp Immunol ; 2024 Jul 16.
Article em En | MEDLINE | ID: mdl-39011978
ABSTRACT
Prevention and treatment of infections are primary goals of treatment of children and adults with primary immune deficiencies due to decreased antibody production. Approaches to these goals include immunoglobulin replacement therapy, vaccination, and prophylactic treatment with antimicrobials. In this review, the infectious and non-infectious complications of antibody deficiencies will be discussed along with the limited number of studies, that support the effective use of the available therapies and to drive the development of new therapies. Some illustrative case studies will be presented and the outlook for additional controlled clinical trials and potential for therapies driven by the underlying disease genetics will be considered.

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article